Holen Sie sich die Stockscreener-App
253.84
1.16%
-2.843
Schlusskurs vom Vortag:
$256.68
Offen:
$257.66
24-Stunden-Volumen:
166.42K
Relative Volume:
0.45
Marktkapitalisierung:
$6.54B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-9.2879
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
+9.56%
1M Leistung:
+3.21%
6M Leistung:
-30.15%
1J Leistung:
-11.12%
1-Tages-Spanne:
$249.65
$257.66
1-Wochen-Bereich:
$229.84
$257.66
52-Wochen-Spanne:
$215.38
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
253.76 | 6.54B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
129.40 | 230.70B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.42 | 154.22B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.65 | 145.74B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.39 | 107.03B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.15 | 44.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Electrophoresis Reagents Market: Trends, Drivers, - openPR.com
Bio-Rad's Management to Participate in Fireside Chat During 2025 - GuruFocus
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference - Business Wire
Bio-Rad Laboratories – Vericheck ddPCR™ Empty-Full Capsid Kit - Labmate Online
Hemoglobinopathy Market Set to Witness Significant Growth - openPR.com
Elisa Analyzer Market Grows Due to Demand for Quick and Accurate - openPR.com
Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued? (NYSE:BIO) - Seeking Alpha
Proteomics Market to Reach $161.9 billion, Globally, by 2035 - openPR.com
Cell-Based Assay Market Top Players- Becton, Dickinson - openPR.com
How To Trade (BIO.B) - news.stocktradersdaily.com
Paper Diagnostics Market Set to Witness Significant Growth by 2025-2032 | Abbott (Alere Inc.), Bio-Rad Laboratories - openPR.com
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
Sample Preparation Market Grows with Automation and Diagnostic - openPR.com
Antimicrobial Susceptibility Testing Market Report Insights, - openPR.com
Molecular Diagnostics Market Sees Strong Growth Driven by Rise - openPR.com
Custom Antibody Market To Hit USD 1,230.09 Billion By 2032 | - openPR.com
Polymerase Chain Reaction Market Set to Witness Significant - openPR.com
Enzyme Linked Immunosorbent Assay Market Deep Research - openPR.com
Bio-Rad Reports First-Quarter 2025 Financial Results - ADVFN
Fund Update: First Pacific Advisors, LP added 214,705 shares of BIO-RAD LABORATORIES ($BIO) to their portfolio - Nasdaq
U.S. Hemoglobinopathy Market 2025-2032: Top Trends & Growth - openPR.com
One Step RT-qPCR Kits Market Top Players- Takara Bio Inc., - openPR.com
Laboratory Proficiency Testing Market Is Booming Worldwide | - openPR.com
Biodetection Market Deep Research 2025-2032 | Bio-Rad - openPR.com
Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report - Yahoo Finance
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Bio-Rad Earnings: Revenue Declines Driven by Weak Academic Research Market; Guidance Lowered - Morningstar
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Call Transcript - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Ra - GuruFocus
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Rad Laboratories | BIO Stock News - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | B - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | BIO Stock News - GuruFocus
Bio-Rad's Steady Business and Stake in Sartorius Driving Long-Term Value - Morningstar
RBC Capital Lowers Price Target for Bio-Rad Laboratories (BIO) | - GuruFocus
RBC Capital Lowers Price Target for Bio-Rad Laboratories (BIO) | BIO Stock News - GuruFocus
Bio-Rad (BIO) Target Price Cut by UBS Amid Macroeconomic Concerns | BIO Stock News - GuruFocus
Bio-Rad (BIO) Sees Price Target Reduced by Citi Analyst After Q1 Report | BIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Biosensors Market Future Business Opportunities 2025-2032 | - openPR.com
UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating - marketscreener.com
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket - Yahoo Finance
Biomarker Testing Market: Trends, Growth, and Key Insights 2025 - openPR.com
Bio-Rad Laboratories Q1 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo
Bio Rad Laboratories Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bio-Rad: Q1 Earnings Snapshot - MySA
Bio-Rad Laboratories Reports Q1 2025 Financial Results - TipRanks
Bio-Rad Laboratories (BIO) Faces Revenue Challenges Amid Market Headwinds - GuruFocus
Bio-Rad Laboratories Q1 2025 Earnings Call Transcript - MarketBeat
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):